HELP YOUR PATIENTS STAND STRONG AGAINST THE FLU WITH THE PROTECTION OF AFLURIA

ABOUT AFLURIA1

  • Afluria is an inactivated influenza vaccine indicated for active immunization against influenza disease caused
    by influenza virus subtypes A and type B present in the vaccine.
  • Afluria is contraindicated in individuals with known severe allergic reaction (eg, anaphylaxis) to any component
    of the vaccine including egg protein, or to a previous dose of any influenza vaccine. Learn more about the Efficacy and Safety of Afluria.
  • AFLURIA PRESENTATIONS
  • AFLURIA DOSING AND ADMINISTRATION
  • PHARMAJET STRATIS NEEDLE-FREE
  • HOW AFLURIA IS MADE

AFLURIA OFFERS YOU THE FLEXIBILITY OF 2 PRODUCT PRESENTATIONS1

Influenza Vaccine
  • Single-use, pre-filled
    syringe (0.5 mL) Thimerosal-Free
  • 5 mL multi-dose vial
    (contains ten 0.5 mL doses)
    with peel-off labels Contains thimerosal as a preservative
  • Neither Afluria presentation is
    made with natural rubber latex1

Afluria is contraindicated in individuals with known severe allergic reaction (eg, anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.

DOSING AND ADMINISTRATION1

  • Intramuscular injection, using needle and syringe, in patients 5 years of age and older*
  • PharmaJet® Stratis® Needle-Free Injector in patients 18 through 64 years of age
  • A single dose is 0.5 mL
Dosing and Administration

*The Advisory Committee on Immunization Practices recommends that Afluria not be used in children 6 months through
8 years of age because of this age group’s increased risk of febrile reactions with CSL’s 2010 Southern hemisphere flu vaccine.

1 or 2 doses depends on vaccination history as per the Advisory Committee on Immunization Practices annual recommendations
on prevention and control of influenza with vaccines.

INNOVATIVE ADMINISTRATION OF AFLURIA WITH THE PHARMAJET STRATIS NEEDLE-FREE INJECTOR2

The combination of Afluria and PharmaJet provides a safe, effective, and needle-free option for
retail pharmacies and medical providers focused on increasing vaccination rates.3,4,5

AFLURIA IS THE ONLY FDA-APPROVED FLU VACCINE FOR ADMINISTRATION WITH
THE PHARMAJET STRATIS NEEDLE-FREE INJECTOR2

FDA APPROVAL WAS BASED ON RESULTS FROM A STUDY PUBLISHED IN THE LANCET2
VIEW EFFICACY & SAFETY RESULTS

How does the PharmaJet Stratis Needle-Free Injector Work?6

  • Delivers Afluria intramuscularly through a narrow, precise fluid stream that penetrates the skin
    in about one-tenth of a second
  • Single-use, 0.5 mL, fixed-volume syringe; auto-disabling; inherent dose accuracy
  • No external power source required—injector tested to 20,000 cycles

Benefits of the PharmaJet Stratis Needle-Free Injector

  • Effectively administers Afluria2,6
  • Safe—eliminates needlestick injuries, sharps management and disposal2
  • Minimal training required6
    • A variety of training options, such as self-guided or online, are available
  • Comfortable—minimizes needle fear and anxiety3,4,5
  • Nearly 90% of those who received their vaccination using PharmaJet indicated that they would choose
    a needle-free injection again for their next vaccination7

Which Patients Can Be Administered Afluria With the PharmaJet Stratis
Needle-Free Injector?1

Adults 18 through 64 years of age who have not experienced a severe allergic reaction (such as
anaphylaxis) to any component of the vaccine, including egg protein, or to a previous dose of any
influenza vaccine.

Visit www.pharmajet.com to Order or Learn More About the PharmaJet Stratis
Needle-Free Injector

AFLURIA IS MANUFACTURED USING THE HIGHEST QUALITY-CONTROL STANDARDS

Afluria is manufactured by Seqirus Pty Ltd. and distributed by Seqirus USA Inc. Seqirus has dedicated production facilities in Holly Springs, North Carolina, Kankakee, Illinois, Melbourne, Australia, and Marburg Germany.

Afluria manufacturing

Each facility is subject to regular inspections by the FDA and other regulatory agencies. To ensure
consistent quality of vaccines, every step of the manufacturing process and supply chain is tightly
controlled, including:

  • Close monitoring of egg production
  • Skillful seed development
  • Temperature- and environment-controlled product distribution

Manufacturing Process

Afluria manufacturing steps 1 - 3

Reliable Distribution of Afluria

Seqirus is a key provider of the influenza vaccine in the world today and strives to meet immunization
needs with a consistent supply of influenza vaccine when and where it is needed.

References: 1. Afluria® [package insert]. King of Prussia, PA: Seqirus USA Inc.; April 2016. 2. McAllister L, Anderson J, Werth K, et al. Needle-free jet injection for
administration of influenza vaccine: a randomised non-inferiority trial. Lancet. 2014;384(9944):674-861. 3. Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in
young adults: prevalence and associations. Am J Trop Med Hyg. 2003;68(3):341-344. 4. Wright S, Yelland M, Heathcote K, Ng S-K. Fear of needles: nature and
prevalence in general practice. Aust Fam Physician. 2009;38(3):172-176. 5. Taddio A, Ipp M, Thivakaran S, et al. Survey of the prevalence of immunization
non-compliance due to needle fears in children and adults. Vaccine. 2012;30(32):4807-4812. 6. Product overview. PharmaJet® Stratis® Needle-Free Injector
Web site. http://pharmajet.com/product/. Accessed March 22, 2016. 7. Data on File. Available from Seqirus as DOF AFL-001.

AT Seqirus, DELIVERING VACCINES IS OUR MISSION AND PROTECTING LIFE IS OUR PASSION

seqirus

The product information presented on this site is for U.S. residents only. Afluria® and Seqirus™ are trademarks of Seqirus UK Limited or its affiliates. PharmaJet® and Stratis® are registered trademarks of PharmaJet Inc. © 2017 Seqirus USA Inc. and/or its affiliates. All rights reserved. 1020 First Avenue, PO Box 60446, King of Prussia, PA 19406-0446

www.seqirus-us.com AFL15-02-0010(2) 08/2016

Important Safety Information

Afluria®, Influenza Vaccine is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. Administration of Afluria with a needle and syringe is approved for use in persons 5 years of age and older. Administration of Afluria with the PharmaJet® Stratis® Needle-Free Injection System is approved for use in persons 18 through 64 years of age only.

Afluria is contraindicated in individuals with known severe allergic reactions (eg, anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.

Administration of CSL's 2010 Southern Hemisphere influenza vaccine was associated with postmarketing reports of increased rates of fever and febrile seizures in children predominantly below the age of 5 years as compared to previous years; these increased rates were confirmed by postmarketing studies. Febrile events were also observed in children 5 to less than 9 years of age.

If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give Afluria should be based on careful consideration of the potential benefits and risks.

If Afluria is administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be diminished.

Afluria should be given to a pregnant woman only if clearly needed.

Afluria has not been evaluated in nursing mothers. It is not known whether Afluria is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Afluria is administered to a nursing woman.

Antibody responses in persons 65 years of age and older were lower after administration of Afluria as compared to younger adult subjects.

In children 5 through 17 years of age, most common injection-site adverse reactions observed in clinical studies of Afluria when administered by needle and syringe were pain, redness, and swelling. The most common systemic adverse events were headache, myalgia, irritability, malaise, and fever.

In adults 18 through 64 years of age, the most common injection-site adverse reactions observed in clinical studies of Afluria when administered by needle and syringe were tenderness, pain, swelling, redness, and itching. The most common systemic adverse reactions observed were muscle aches, headache, and malaise.

In adults 18 through 64 years of age, the most common injection-site adverse reactions observed in clinical studies of Afluria when administered by the PharmaJet Stratis Needle-Free Injection System up to 7 days post-vaccination were tenderness, swelling, pain, redness, itching, and bruising. The most common systemic adverse events within this period were myalgia, malaise, and headache.

In adults 65 years of age and older, the most common injection-site adverse reactions observed in clinical studies of Afluria when administered by needle and syringe were tenderness and pain.

Vaccination with Afluria may not protect all individuals.

Please see full prescribing information for Afluria.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

US/AFL/0716/0045b 07/2016